Share ownership AbbVie Inc.

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - NYSE Other stock markets 04:02:19 2026-06-12 pm EDT			5-day change	1st Jan Change
227.73 ^USD	+1.32%		+0.22%	-0.33%

Jun. 12	AbbVie Says Leukemia Combination Therapy Shows Long-Term benefit Phase 3 study	MT
Jun. 12	AbbVie Presents New Phase 3 Data on Fixed-Duration Venetoclax-Based Combination At EHA 2026 Congress	CI

Share class: AbbVie Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,843,870,020	1,764,722,730 ( 95.71 %)	77,077,199 ( 4.18 %)	95.71 %

Major shareholders: AbbVie Inc.

Name	Stocks	%	Valuation
Vanguard Capital Management LLC 6.502 %	114,880,324	6.502 %	25 012 M $
BlackRock Advisors LLC 6.391 %	112,913,460	6.391 %	24 584 M $
STATE STREET CORPORATION 4.597 %	81,217,516	4.597 %	17 683 M $
JPMorgan Investment Management, Inc. 3.212 %	56,741,691	3.212 %	12 354 M $
Vanguard Portfolio Management LLC 2.803 %	49,523,078	2.803 %	10 782 M $
Geode Capital Management LLC 2.645 %	46,737,581	2.645 %	10 176 M $
Eaton Vance Management 2.152 %	38,016,773	2.152 %	8 277 M $
BlackRock Life Ltd. 1.893 %	33,448,007	1.893 %	7 282 M $
Capital Research & Management Co. (Global Investors) 1.769 %	31,254,786	1.769 %	6 805 M $
Norges Bank (13F) 1.453 %	25,668,761	1.453 %	5 589 M $
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Stocks	%	Valuation
Caixa DTVM SA 0.001033 %	291,962	0.001033 %	4 M $
XP Allocation Asset Management Ltda. 0.000003 %	809	0.000003 %	10 962 $

Breakdown by shareholder type

Institutional	59.7%
Others	8.72%
State Street Corp.	4.6%
Schweizerische Nationalbank	0.29%
Sumitomo Mitsui Trust Group, Inc.	0.22%
Manulife Financial Corp.	0.15%
Governments	0.14%
Swedbank AB	0.14%
Fifth Third Bancorp	0.12%
Danske Bank A/S	0.07%
Individuals	0.07%
Menora Mivtachim Holdings Ltd.	0.06%
SEI Investments Co.	0.06%
ABN AMRO Bank NV	0.05%
Regions Financial Corp.	0.04%
Cincinnati Financial Corp.	0.03%
ING Groep NV	0.03%
Zurich Insurance Group AG	0.02%
Pinnacle Financial Partners, Inc.	0.02%
Banco Bilbao Vizcaya Argentaria SA	0.02%
The Bank of Nova Scotia	0.02%
Migdal Insurance & Financial Holdings Ltd.	0.02%
Cullen/Frost Bankers, Inc.	0.02%
Silvercrest Asset Management Group, Inc.	0.01%
Hikari Tsushin, Inc.	0.01%
Banque Cantonale Vaudoise	0.01%
Hancock Whitney Corp.	0.01%
Münchener Rückversicherungs-Gesellschaft AG	0.01%
The Allstate Corp.	0.01%
Peapack-Gladstone Financial Corp.	0.01%
Unknown	25.32%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	56.39%
United Kingdom	7.71%
Canada	2.6%
Norway	1.6%
France	0.83%
Sweden	0.76%
Japan	0.74%
Switzerland	0.6%
Australia	0.55%
Denmark	0.47%
Netherlands	0.46%
Germany	0.42%
South Korea	0.3%
Hong Kong	0.23%
Luxembourg	0.18%
Italy	0.16%
Belgium	0.11%
Israel	0.09%
Ireland	0.08%
Individuals	0.07%
Spain	0.06%
Finland	0.06%
Austria	0.04%
New Zealand	0.03%
Liechtenstein	0.03%
Czech Republic	0.03%
Russia	0.02%
Brazil	0.02%
Singapore	0.02%
Malaysia	0.01%
China	0.01%
Saudi Arabia	0.01%
South Africa	0.01%

Based on 1000 largest holdings

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).

Employees

57,000

Sector

Pharmaceuticals

More about the company